Nephros Inc
NEPH- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0001196298
In the last 90 days, Nephros Inc insiders filed 1 open-market purchase and 0 sales; 35 institutions reported holding it in 13F filings for Q3 2026, worth $9.54M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 19, 2026
- $30.9M
- Insider buysLast 90 days, $22.1K in total
- 1
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ3 2026, +2 vs. previous quarter
- 35
- 13F valueReported value at the end of Q3 2026
- $9.54M
- Superinvestors holdingAt the end of Q3 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $18.8M
- +32.7% year over year
- Net income, FY2025
- $1.19M
- +1,513.5% year over year
- Free cash flow, FY2025
- –
- No comparable prior period
- Revenue, Q3 FY2026
- $5.62M
- +18.0% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 11.9K
- Shares sold short
- Change
- −3.53K
- −22.9% vs. previous
- Days to cover
- 1.00
- At average daily volume
Superinvestors holding NEPH, Q3 2026
Go to the superinvestors tabNo superinvestor reported holding NEPH at the end of Q3 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Nephros Inc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 18, 2026 (view filing)4:57 PM ET | Nov 16-17 | 2 days | Amron Arthur HDirector | PPurchase | +7.50K | $2.94 | +$22.1K | +4.6%169.6K after | 2 lots |
| May 30, 2024 (view filing) | May 28-30 | 2 days | Amron Arthur HDirector | PPurchase | +5.00K | $2.23 | +$11.2K | +5.1%103.5K after | 2 lots |
| May 16, 2024 (view filing) | May 16 | Same day | Banks Robert R. Jr.President and CEO | PPurchase | +50.0K | $2.24 | +$112.0K | +250.0%70.0K after | |
| Mar 14, 2024 (view filing) | Mar 12 | 2 days | Amron Arthur HDirector | PPurchase | +7.00K | $2.45 | +$17.1K | New position7.00K after | |
| Dec 11, 2023 (view filing) | Dec 7 | 4 days | Banks Robert R. Jr.President and CEO | PPurchase | +18.0K | $2.20 | +$39.6K | +900.0%20.0K after | |
| Aug 15, 2023 (view filing) | Aug 14-15 | 1 day | Banks Robert R. Jr.President and CEO | PPurchase | +2.00K | $1.68 | +$3.36K | New position2.00K after | 2 lots |
| Aug 23, 2021 (view filing) | Aug 20 | 3 days | Lobo Wesley S.Chief Marketing Officer | PPurchase | +1.00K | $7.92 | +$7.92K | +2.5%41.6K after | |
| Aug 19, 2021 (view filing) | Aug 18 | 1 day | Gwydir TomDirector | PPurchase | +5.00K | $7.64 | +$38.2K | +82.9%11.0K after | |
| Aug 18, 2021 (view filing) | Aug 17-18 | 1 day | Astor AndrewPresident & CEO | PPurchase | +5.00K | $7.72 | +$38.6K | +6.9%78.0K after | 2 lots |
Top 10 13F holders, Q3 2026
See all 35 holdersThe largest institutional positions in Nephros Inc at the end of Q3 2026; share changes are against Q2 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Topline Capital Management, LLC | 535,698 | $1.99M | 0.44% | 00.0% | Unchanged |
| Massachusetts Institute of Technology | 346,813 | $1.29M | 0.19% | +346,813 | New |
| Wexford Capital LP | 231,068 | $829.3K | 0.11% | −3,369,484−93.6% | Reduced |
| Vanguard Capital Management LLC | 198,643 | $737.0K | 0.00% | 00.0% | Unchanged |
| Johns Hopkins University | 187,857 | $696.9K | 0.05% | +187,857 | New |
| Meritage Group LP | 173,407 | $643.3K | 0.02% | +173,407 | New |
| Morgan Stanley | 123,915 | $459.7K | 0.00% | −5,000−3.9% | Reduced |
| Blackstone Group Inc. | 115,605 | $428.9K | 0.00% | +115,605 | New |
| Bard Associates Inc | 115,528 | $428.6K | 0.10% | −2,475−2.1% | Reduced |
| Renaissance Technologies LLC | 71,100 | $263.8K | 0.00% | −6,404−8.3% | Reduced |
Holders of 5% or more of NEPH
See all 2 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Nephros Inc.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Topline Capital Management, LLC | 13G/A | 6.40%705.7K shares | +0.80 ppfrom 5.60% | Nov 14, 20252 filings | Nov 16, 2026 | SEC |
| Davidson Charles E | 13G | 5.68%616.9K shares | New | Sep 16, 20261 filing | Sep 16, 2026 | SEC |